Syn 1002

Drug Profile

Syn 1002

Alternative Names: PAT; Peptide analogue of thymulin; SYN 1002; Syn1002

Latest Information Update: 31 May 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator INSERM
  • Developer CLL PHARMA
  • Class Analgesics; Anti-inflammatories; Antirheumatics; Oligopeptides
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Crohn's disease; Pain
  • No development reported Neuropathic pain; Rheumatoid arthritis

Most Recent Events

  • 31 May 2016 Phase-I development is ongoing for Pain and Crohn's disease in France (CII PHARMA pipeline, May 2016)
  • 19 May 2016 No recent reports on development identified - Phase-I for Neuropathic pain and Rheumatoid arthritis in France (unspecified route)
  • 25 Jun 2004 Preclinical trials in Neuropathic pain in France (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top